
04/18/2025
A standardized SLIT tablet for dust mite allergies that was previously available for adults is now approved for children 5-11yo. Read the article and Dr. Schroeder's thoughts at the end of the story.
"As a standardized SLIT tablet, Odactra’s FDA approval for children aged 5 to 11 years expands access to a noninvasive, disease-modifying treatment that may be covered by insurance. While Odactra lacks the dosing flexibility and multi-allergen customization of SLIT drops (and allergy shots), it provides a standardized, convenient option for children with house dust mite as a primary trigger. For families needing insurance-supported care, or for clinics without expertise in or access to customized SLIT, this offers a meaningful step forward to optimizing dust mite treatment options for children."
In February, the FDA approved the Odactra tablet, a sublingual immunotherapy, to treat house dust mite-induced allergic rhinitis in patients aged 5 to 11 years, according to a manufacturer-issued press release.As Healio previously reported, Odactra (ALK) was approved for patients aged 12 to 17 years...